PMID: 29485118Feb 28, 2018Paper

Target-specific delivery of doxorubicin to human glioblastoma cell line via ssDNA aptamer

Journal of Biosciences
Abdullah Tahir BayracHuseyin Avni Oktem

Abstract

Targeted drug delivery approaches have been implementing significant therapeutic gain for cancer treatment since last decades. Aptamers are one of the mostly used and highly selective targeting agents for cancer cells. Herein, we address a nano-sized targeted drug delivery approach adorned with A-172 glioblastoma cell-line-specific single stranded DNA (ssDNA) aptamer in which the chemotherapeutic agent Doxorubicin (DOX) had been conjugated. DNA aptamer, GMT-3, was previously selected for specific recognition of glioblastoma and represented many advantageous characteristics for drug targeting purposes. Flow cytometry analysis proved the binding efficiency of the specific aptamer to tumour cell lines. Celltype- specific toxicity of GMT-3:DOX complex was showed by XTT assay and terminated cytotoxic effects were screened for both target cell and a control breast cancer cell line. The result of this contribution demonstrated the potential utility of GMT-3 aptamer-mediated therapeutic drug transportation in the treatment of gliomas specifically. It was concluded that aptamer-mediated drug delivery can be applied successfully for clinical use.

Related Concepts

Related Feeds

Breast Cancer: Therapeutic Approaches

Several different therapeutic approaches are used to treat breast cancer. These include chemotherapy, hormonal therapy, targeted therapy, and Immunotherapy. Discover the latest research on breast cancer therapeutic approaches here.

Related Papers

Dalton Transactions : an International Journal of Inorganic Chemistry
Weijia NiuAdam S Veige
The Anatomical Record : Advances in Integrative Anatomy and Evolutionary Biology
Wanming LiJin Fang
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
Brian J HickePaul G Schmidt
© 2022 Meta ULC. All rights reserved